ERYtech Pharma Announces The Decision Of USPTO To Extend The Additional Exclusivity Period Of Its Core Process Patent To Almost 4 Years

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LYON, France--(BUSINESS WIRE)--Regulatory News:

ERYTECH (NYSE Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces its received final notification of allowance for the granting of its core process patent in the United States in which the term of exclusivity has been further extended from two to almost four years.

This patent entitled “Lysis/Resealing Process and Device for Incorporating an Active Ingredient, in particular Asparaginase or Inositol Hexaphosphate, in Erythrocytes“ describes and claims the process and methods for preparing erythrocytes which reproducibly contain a well-defined amount of active ingredient for use as a pharmaceutical product. This patent is the core protection of the technology platform and products developed by ERYTECH, including the GRASPA® product used in Acute Lymphoblastic Leukemia and in Acute Myeloid Leukemia.

Help employers find you! Check out all the jobs and post your resume.

Back to news